Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer – Results from the prospective multi-center randomized ADEBAR trial
-
Published:2016-06
Issue:
Volume:27
Page:69-77
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Schwentner LukasORCID,
Harbeck Nadia,
Singer Susanne,
Eichler Martin,
Rack Brigitte,
Forstbauer Helmut,
Wischnik Arthur,
Scholz Christoph,
Huober Jens,
Friedl Thomas W.P.,
Weissenbacher Tobias,
Härtl Kristin,
Kiechle Marion,
Janni Wolfgang,
Fink Visnja
Subject
General Medicine,Surgery
Reference27 articles.
1. Classical CMF vs a 3-weekly intravenous CMF schedule;Engelsman;Eur J Cancer,1991
2. Randomized trial of intensive cyclophosphamide, epirubicin, and fuorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer;Levine;J Clin Oncol,1998
3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials;Early breast cancer trialists collaborative group (EBCTCG);Lancet,2005
4. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
5. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献